FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales